Compare MPLX LP (MPLX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs ResMed Inc. — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: MPLX LP is far larger — about 2× ResMed Inc.'s market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MPLX | RMD | |
|---|---|---|
Market Cap | $57.97B | $28.81B |
Sector | Technology | Health |
52-Week High | $59.17 | $293.73 |
52-Week Low | $47.80 | $182.82 |
Enterprise Value | $82.60B | $27.99B |
Dividend Yield | 7.54% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.13, showing modest daily gains of 0.12%. The stock maintains a bullish technical outlook with strong moving average signals, while fundamentals reveal robust profitability with 41.24% net margins and consistent earnings beats in recent quarters. Recent news highlights the company's resilient midstream business model and attractive dividend yield, with analyst consensus strongly favoring the stock.
Outlook remains positive given the 71% buy rating consensus and $60 price target representing 5% upside. Key risks include energy market volatility and the Q1 2026 earnings miss, but the company's fee-based contracts and Permian Basin exposure provide stability. The sustainable dividend and strong cash flow generation support long-term value for income-focused investors.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
